Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novo Nordisk, Sun Pharmaceutical endocrine/metabolic news

In a 2-1 decision, the U.S. Court of Appeals for the Federal Circuit upheld a lower court ruling that a claim in a Novo Nordisk patent related to the use

Read the full 307 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE